University Health Network Princess Margaret Cancer Center LAO
Welcome,         Profile    Billing    Logout  
 69 Trials 
776 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kaley, Thomas
POPLAR-NF2, NCT05130866: Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas

Recruiting
2/3
92
US
REC-2282, AR-42, OSU-HDAC42, NSC-D736012, Placebo
Recursion Pharmaceuticals Inc.
Neurofibromatosis Type 2
01/27
07/27
NCT00588523: Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma

Completed
2
60
US
temozolomide followed by high dose busulfan and thiotepa
Memorial Sloan Kettering Cancer Center, University of Calgary, Northwestern University, Northwestern Memorial Hospital, Massachusetts General Hospital, Schering-Plough
CNS Cancer, CNS BRAIN
02/23
02/23
NCT03220646: Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors

Active, not recruiting
2
64
US
abemaciclib
Memorial Sloan Kettering Cancer Center, Eli Lilly and Company
Brain Tumor
07/25
07/25
A071401, NCT02523014: Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients with Progressive Meningiomas

Recruiting
2
124
US
Vismodegib, GDC-0449, FAK Inhibitor GSK2256098, Capivasertib, AZD5363, Abemaciclib
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), GlaxoSmithKline, Genentech, Inc., Brain Science Foundation
Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
01/26
01/28
NCT05425004: Cabozantinib for Patients With Recurrent or Progressive Meningioma

Recruiting
2
24
US
Cabozantinib, XL184, Cometriq, Cabometyx, BMS907351
Baptist Health South Florida, Exelixis
Meningioma
11/25
05/28
NCT05859334: Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment

Suspended
2
35
Canada, US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Erdafitinib, Balversa, JNJ 42756493, JNJ-42756493, JNJ42756493, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Optical Coherence Tomography, OCT, Optical Coherence Tomography (OCT)
National Cancer Institute (NCI)
Recurrent Glioblastoma, IDH-Wildtype, Recurrent WHO Grade 2 Glioma, Recurrent WHO Grade 3 Glioma
10/26
10/26
NCT05303519: Safusidenib Phase 2 Study in IDH1 Mutant Glioma

Active, not recruiting
2
95
US
safusidenib, DS-1001b, AB-218
Nuvation Bio Inc., AnHeart Therapeutics Inc.
Glioma
03/27
07/27
NCT04606316: Surgical Nivolumab And Ipilimumab For Recurrent GBM

Active, not recruiting
1
63
US
Nivolumab-Placebo, Nivolumab, Opdivo, Ipilimumab-Placebo, Ipilimumab, Yervoy, Surgery, Resection
Patrick Wen, MD, Bristol-Myers Squibb
Glioblastoma, GBM, Glioblastoma Multiforme, Grade IV Astrocytoma
06/25
12/25
NCT02658279: Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype

Active, not recruiting
N/A
27
US
Pembrolizumab, (MK-3475)
Memorial Sloan Kettering Cancer Center, Merck Sharp & Dohme LLC, M.D. Anderson Cancer Center, Dana-Farber Cancer Institute, University of California, San Francisco, Huntsman Cancer Institute/ University of Utah, University of California, Los Angeles, University of Miami
Glioma, Recurrent Malignant Glioma
01/25
01/25
NCT01892397: Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma

Active, not recruiting
N/A
6
US
Optune (NovoTTF-100A)
Memorial Sloan Kettering Cancer Center, NovoCure Ltd., Columbia University, University of Cincinnati, University of Colorado, Denver, University of Miami, Cedars-Sinai Medical Center
Brain Cancer
06/25
06/25
Sullivan, Ryan J
DAR-UM-2, NCT05987332: IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Recruiting
2/3
420
Europe, Canada, US, RoW
IDE196, Darovasertib, Crizotinib, XALKORI, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Nivolumab, Opdivo, Dacarbazine, DTIC-Dome
IDEAYA Biosciences
Metastatic Uveal Melanoma
01/27
01/28
NCT03149029: Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma

Active, not recruiting
2
16
US
Pembrolizumab, Keytruda, Dabrafenib, Tafinlar, Trametinib, Mekinist
Massachusetts General Hospital, Merck Sharp & Dohme LLC
Metastatic Melanoma
12/21
12/24
NCT05034536: PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma

Recruiting
2
36
US
Pembrolizumab, Keytruda, Infliximab, AVSOLA, Ixifi, Remicade, Renflexis, Placebo, Relatlimab, Nivolumab
Massachusetts General Hospital, Massachusetts Institute of Technology
Metastatic Melanoma
06/25
06/26
NCT04356729: A Phase II Trial of PD-L1 Therapy Combined with Anti-VEGF Therapy in Unresectable or Metastatic Melanoma

Recruiting
2
30
US
Atezolizumab, Tecentriq, Bevacizumab, Avastin, Mvasi
Elizabeth Buchbinder, MD, Genentech, Inc.
Clinical Stage III Cutaneous Melanoma AJCC V8, Stage IV Melanoma, Unresectable Stage III Cutaneous Melanoma, Unresectable Stage IV Cutaneous Melanoma
03/25
09/25
NCT05428007: Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma

Recruiting
2
69
US
Sarilumab, REGN88, Ipilimumab Injection, BMS-734016, MDX010, MDX-CTLA4, Nivolumab/Relatlimab, BMS-986213
NYU Langone Health
Melanoma, Unresectable Melanoma
06/25
12/25
Keynote-942, NCT03897881: An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)

Checkmark KEYNOTE-942 trial combination with Keytruda for the adjuvant treatment of patients with stage III/IV melanoma
Dec 2022 - Dec 2022: KEYNOTE-942 trial combination with Keytruda for the adjuvant treatment of patients with stage III/IV melanoma
Checkmark Results in combination with mRNA-4157 from Keynote-942 trial for high-risk melanoma
Dec 2022 - Dec 2022: Results in combination with mRNA-4157 from Keynote-942 trial for high-risk melanoma
Recruiting
2
267
US, RoW
mRNA-4157, Pembrolizumab
ModernaTX, Inc., Merck Sharp & Dohme LLC
Melanoma
09/29
09/29
NCT02212743: Potential Anti-cancer Activity of Increasing Doses of AZD5363 + Dabrafenib in Different Treatment Schedules and Solid Tumors That Are Metastatic or Cannot be Removed by Surgery

Recruiting
1/2
180
US, Europe, RoW
AZD5363 and Dabrafenib administered orally, Drug: Dabrafenib, Other Names:, Tafinalar, GSK2118436, Dabrafenib 150 mg orally will be administered. Capsules with unit dose strengths of 50 mg or 75 mg, Biological: AZD5363, CAS 1143532-39-1
Conquer Cancer Foundation, Cancer Research Institute, Melanoma Research Foundation
Advanced Solid Malignancy, Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, Tumour Response, Advanced or Metastatic Breast Cancer, Ovarian Cancer, Cervical Cancer, Endometrial Cancer, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma, Unspecified Adult Solid Tumor, Protocol Specific, PIK3CA, AKT1, ER+, HER2+
12/14
09/15
NCT01970956: Dabrafenib/Trametinib/Navitoclax In Braf Mutant Melanoma

Not yet recruiting
1/2
18
US
Navitoclax, ABT-263, Dabrafenib, GSK2118436, GSK2118436A (free base), Tafinlar, Trametinib, GSK1120212, JTP-74057, JTP-78296, JTP-75303, Mekinist
Massachusetts General Hospital, National Cancer Institute (NCI)
BRAF Mutant Melanoma, Solid Tumors
01/17
09/20
NCI-2013-02103, NCT01989585: Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma

Active, not recruiting
1/2
75
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Dabrafenib, BRAF Inhibitor GSK2118436, GSK 2118436, GSK 2118436A, GSK-2118436, GSK-2118436A, GSK2118436, GSK2118436A, Echocardiography, EC, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Navitoclax, A-855071.0, ABT-263, BcI-2 Family Protein Inhibitor ABT-263, Pharmacological Study, Trametinib, GSK 1120212, GSK 212, GSK-1120212, GSK-212, GSK1120212, GSK212, JTP 74057, JTP-74057, JTP74057, MEK Inhibitor GSK1120212
National Cancer Institute (NCI)
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Malignant Solid Neoplasm, Metastatic Melanoma, Unresectable Melanoma
12/25
12/25
IMM6415-101, NCT06208124: A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors

Recruiting
1/2
240
US
IMM-6-415
Immuneering Corporation
Advanced Solid Tumor (Phase 1), Pancreas Adenocarcinoma, Non-small Cell Lung Cancer, Malignant Melanoma (Cutaneous)
06/27
07/27
GIM531-CT01, NCT06425926: Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

Recruiting
1/2
84
US
GIM-531, Anti-PD-1 monoclonal antibody
Georgiamune Inc
Melanoma Stage IV, Solid Tumor
12/25
11/26
NCT03520075 / 2018-004568-72: Study of ASTX029 in Subjects With Advanced Solid Tumors

Active, not recruiting
1/2
190
Europe, US
ASTX029
Taiho Oncology, Inc.
Solid Tumor, Adult
08/24
12/25
KEYNOTE-E64, NCT04787042: Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

Recruiting
1/2
316
US
ST-067, Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA], GAZYVA, pembrolizumab, KEYTRUDA®
Simcha IL-18, Inc., Merck Sharp & Dohme LLC
Cancer, Solid Tumor, Melanoma, Renal Cell Carcinoma, Triple-negative Breast Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Carcinoma, MSI-High
06/25
12/25
FIH, NCT04104776 / 2020-004952-14: A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas

Recruiting
1/2
210
Europe, US, RoW
CPI-0209
Constellation Pharmaceuticals
Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant, Prostatic Neoplasms, Castration-Resistant, Endometrial Cancer, Ovarian Clear Cell Carcinoma
12/25
03/26
Nautilus, NCT05340621: NAUTILUS: OKI-179 Plus Binimetinib in Patients With Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)

Active, not recruiting
1/2
36
US
OKI-179 + binimetinib
OnKure, Inc.
RAS Mutation, NRAS Gene Mutation, Melanoma
03/26
04/26
NCT05415072 / 2021-003380-95: A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas

Recruiting
1/2
124
Europe, US, RoW
DYP688
Novartis Pharmaceuticals, Novartis Pharma AG
Metastatic Uveal Melanoma
09/25
09/25
START-001, NCT05592626: A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants with Advanced Solid Tumors

Recruiting
1/2
365
Europe, Canada, US
STAR0602
Marengo Therapeutics, Inc.
Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm, Neoplasms by Site, Papillomavirus Infection, Epstein-Barr Virus Infections, Carcinoma, Neoplasms, Vulvar Neoplasms, Vulvar Diseases, Abdominal Neoplasm
10/26
10/26
NCT05580770: Mirdametinib + BGB-3245 in Advanced Solid Tumors

Active, not recruiting
1/2
23
US, RoW
Mirdametinib, PD-0325901, BGB-3245
SpringWorks Therapeutics, Inc.
Advanced Solid Tumor
10/26
06/27
NCT02097225: Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Terminated
1
22
US
Dabrafenib, BRAF Inhibitor GSK2118436, GSK-2118436, GSK-2118436A, GSK2118436, Laboratory Biomarker Analysis, Onalespib, AT 13387, AT-13387, AT13387, Pharmacological Study, Trametinib, GSK 1120212, GSK-1120212, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212
National Cancer Institute (NCI)
BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Solid Neoplasm
03/19
10/22
NCT04109456: IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma

Active, not recruiting
1
120
US, RoW
IN10018, BI 853520, Cobimetinib, Cotellic, Atezolizumab
InxMed (Shanghai) Co., Ltd.
Metastatic Melanoma
06/25
12/25
NCT04418167: JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

Suspended
1
71
US
JSI-1187, Dabrafenib, TAFINLAR
JS InnoPharm, LLC
Solid Tumors
06/24
12/24
STK-012-101, NCT05098132: STK-012 Monotherapy and in Combination Therapy in Patients with Solid Tumors

Recruiting
1
202
US
STK-012, pembrolizumab, pemetrexed, carboplatin
Synthekine
Advanced Solid Tumor, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Malignant Melanoma, Renal Cell Carcinoma, Cervical Cancer, Microsatellite Instability High, Gastric Cancer, GastroEsophageal Cancer, Urothelial Carcinoma, Mismatch Repair Deficiency
10/27
10/27
NCT04169321: Granzyme B PET Imaging Drug as a Predictor of Immunotherapy Response to Checkpoint Inhibitors

Recruiting
1
30
US, RoW
Single Arm, [68Ga]-NOTA-hGZP, CSB-111
Cytosite Biopharma Inc., Massachusetts General Hospital, University of Alabama at Birmingham, Chang Gung Memorial Hospital
Solid Tumor, Unspecified, Adult, Lymphoma
12/25
02/26
GARNET, NCT02715284: Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

Checkmark MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer
Dec 2022 - Dec 2022: MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer
Checkmark Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Sep 2022 - Sep 2022: Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Checkmark Approved for recurrent or advanced endometrial cancer
More
Recruiting
1
740
Europe, Canada, US, RoW
Dostarlimab
Tesaro, Inc.
Neoplasms
05/26
10/27
NCT01840527: Utility of Novel BRAF Test for Melanoma

Completed
N/A
220
US
Massachusetts General Hospital, National Cancer Institute (NCI)
Melanoma
03/17
09/22
NCT02784366: GI Complications in Cancer Immunotherapy Patients

Recruiting
N/A
100
US
Massachusetts General Hospital, Dana-Farber Cancer Institute
Malignant Melanoma
03/24
03/24
Renouf, Daniel
A021806, NCT04340141: Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer

Recruiting
3
352
Canada, US
Oxaliplatin, Irinotecan Hydrochloride, Leucovorin Calcium, Fluorouracil, Resection, Questionnaire Administration
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Pancreatic Adenosquamous Carcinoma, Resectable Pancreatic Adenocarcinoma, Pancreatic Cancer
01/26
11/30
CAPTUR, NCT03297606: Canadian Profiling and Targeted Agent Utilization Trial

Recruiting
2
720
Canada
Olaparib, Dasatinib, Nivolumab plus Ipilimumab, Axitinib, Bosutinib, Crizotinib, Palbociclib, Sunitinib, Temsirolimus, Erlotinib, Trastuzumab plus Pertuzumab, Vemurafenib plus Cobimetinib, Vismodegib, Tucatinib
Canadian Cancer Trials Group, AstraZeneca, Bristol-Myers Squibb, Hoffmann-La Roche, Pfizer, Seagen Inc.
Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
01/26
01/27
CAPTIV-8, NCT04273061: Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity

Recruiting
2
200
Canada
Atezolizumab, TECENTRIQ
British Columbia Cancer Agency, Hoffmann-La Roche
Breast Cancer, Lung Cancer, Gastrointestinal Cancer, Genitourinary Cancer, Gynecologic Cancer, Sarcoma, Unknown Primary Tumors, Head and Neck Cancer, Skin Cancer
10/27
10/27
SLC-0111-17-01, NCT03450018: A Study of SLC-0111 and Gemcitabine for Metastatic Pancreatic Ductal Cancer in Subjects Positive for CAIX

Terminated
1/2
6
Canada
SLC-0111, WBI-5111, Gemcitabine Injection, Gemcitabine
British Columbia Cancer Agency, Canadian Cancer Society (CCS), SignalChem Lifesciences Corporation
Metastatic Pancreatic Ductal Adenocarcinoma
05/24
05/24
NCT02869802: Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis

Recruiting
N/A
190
Canada
Tumour Biopsy, Serial Collection of Plasma and Serum Samples
British Columbia Cancer Agency, Terry Fox Research Institute, BC Cancer Foundation, Pancreas Centre BC, American Society of Clinical Oncology
Cancer, Pancreatic Cancer
12/26
12/27
COMPARISON, NCT03364621: Comprehensive Genomic Profiling of Colorectal Cancer Patients With Isolated Liver Metastases to Understand Response & Resistance to Cancer Therapy

Active, not recruiting
N/A
17
Canada
University Health Network, Toronto, Terry Fox Research Institute, British Columbia Cancer Agency
Colorectal Cancer, Colorectal Cancer Metastatic, Hepatic Metastases
06/25
06/25
ACCELERATE, NCT06574620: Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment

Not yet recruiting
N/A
200
Canada
Genetic testing, Optional biopsy
British Columbia Cancer Agency, Terry Fox Research Institute, BC Cancer Foundation
Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Ductal Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma
12/28
12/31
PEGASUS, NCT05132244: Monitoring and Managing Glucose Levels in People With Pancreatic Cancer

Recruiting
N/A
50
Canada
Endocrinologist-directed target blood glucose level 4-10 mmol/L using data from a continuous glucose monitor (CGM), Standard Care
British Columbia Cancer Agency, University of British Columbia
Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, Hyperglycemia
04/26
04/27
Jain, Rohit
KEYNOTE-D78, NCT04879329: A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Recruiting
2
372
Europe, Canada, Japan, US, RoW
disitamab vedotin, RC48-ADC, pembrolizumab, KEYTRUDA®
Seagen Inc., Merck Sharp & Dohme LLC
Urothelial Carcinoma
11/26
05/28
CA209-63Y, NCT04863885: Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients

Checkmark Data from trial in combination with Ipilimumab and Nivolumab for Urothelial Carcinoma at ESMO 2021
Jul 2021 - Jul 2021: Data from trial in combination with Ipilimumab and Nivolumab for Urothelial Carcinoma at ESMO 2021
Active, not recruiting
1/2
46
US
Ipilimumab, Yervoy, Nivolumab, Opdivo, Sacituzumab govitecan, Trodelvy
H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb, Gilead Sciences
Metastatic Urothelial Carcinoma
04/26
04/27
MCC-22344, NCT06193486: Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC

Recruiting
1
30
US
MSGV1-PSCA-8T28Z, Fludarabine, Fludara, Cyclophosphamide
H. Lee Moffitt Cancer Center and Research Institute
Metastatic Castration-resistant Prostate Cancer
01/29
12/33
NCT04963153: Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy

Recruiting
1
30
Canada, US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Enfortumab Vedotin, AGS 22ME, AGS-22M6E, Anti-Nectin 4 ADC ASG-22CE, Anti-nectin-4 Monoclonal Antibody-Drug Conjugate AGS-22M6E, ASG 22CE, ASG-22CE, ASG22CE, Enfortumab Vedotin-ejfv, Padcev, Erdafitinib, Balversa, JNJ 42756493, JNJ-42756493, JNJ42756493, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning
National Cancer Institute (NCI)
Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma, Recurrent Ureter Urothelial Carcinoma, Recurrent Urethral Urothelial Carcinoma, Recurrent Urothelial Carcinoma, Stage IIIB Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8
09/25
09/25
NCT03837821: (CLONEVO): Cell cycLe inhbitiON to Target the EVolution of UrOthelial Cancer

Active, not recruiting
1
20
US
Abemaciclib
Weill Medical College of Cornell University, Eli Lilly and Company
Bladder Cancer
07/24
12/25
MCC-20575, NCT04610671: Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC

Active, not recruiting
1
21
US
CG0070, Nivolumab
H. Lee Moffitt Cancer Center and Research Institute, CG Oncology, Inc., Richard M. Shulze Family Foundation
Muscle-Invasive Bladder Carcinoma, Bladder Cancer
01/25
01/26
NCT05367518: Colonisation Efficacy of Oral Probiotic Fast Melt Powder

Recruiting
N/A
20
RoW
Probiotic Streptococcus salivarius K12 Fast Melt Powder 1 Billion colony forming units /g), Probiotic Streptococcus salivarius K12 Fast Melt Powder 100 Million colony forming units /g)
BLIS Technologies Limited
Microbial Colonization
05/22
06/22
NCT05375396: Microbial Colonization of Dairy Free Oral Probiotics

Recruiting
N/A
30
RoW
Streptococcus salivarius M18 lozenges, Streptococcus salivarius M18 dairy free lozenges
John Hale
Microbial Colonization
07/22
08/22
NCT05375383: Microbial Colonization of Oral Probiotics

Recruiting
N/A
60
RoW
Streptococcus salivarius K12 lozenge, Probiotic S. salivarius K12 lozenges containing prebiotic A, Probiotic S. salivarius K12 lozenges containing prebiotic B, Probiotic S. salivarius K12 lozenges containing prebiotics A and B, Probiotic S. salivarius K12 powder, Probiotic S. salivarius K12 powder containing prebiotic A, Probiotic S. salivarius K12 powder containing prebiotic B, Probiotic S. salivarius K12 powder containing prebiotics A and B, Probiotic S. salivarius M18 lozenges, Probiotic S. salivarius M18 lozenges containing prebiotic A, Probiotic S. salivarius M18 lozenges containing prebiotic B, Probiotic S. salivarius M18 + lozenges containing prebiotic A and B
BLIS Technologies Limited
Microbial Colonization
08/22
09/22
NCT05480020: Probiotic Toothpaste for Microbial Colonization

Recruiting
N/A
30
RoW
Streptococcus salivarius M18 toothpaste
John Hale
Microbial Colonization
09/22
10/22
NCT05750381: Assessment of Colonisation and Skin Quality Parameter Improvement by Probiotic Micrococcus Luteus Q24 Balm in Healthy Adults.

Recruiting
N/A
20
RoW
Micrococcus luteus Blis Q24 balm, Placebo balm
BLIS Technologies Limited
Microbial Colonization
03/23
04/23
Bradbury, Penelope A
LIBRETTO-432, NCT04819100 / 2020-005191-35: A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

Recruiting
3
170
Europe, Canada, Japan, US, RoW
Selpercatinib, LY3527723, LOXO-292, Placebo
Loxo Oncology, Inc., Eli Lilly and Company
Carcinoma, Non-Small-Cell Lung
05/27
08/32
CCTG IND.238A, NCT03847649: A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies

Recruiting
2
60
Canada
Durvalumab, Prednisone, Tremelimumab
Canadian Cancer Trials Group, AstraZeneca
Cancer
04/30
04/31
NCT05714891: Neoadjuvant Platform Trial in Non-Small Cell Lung Cancer

Active, not recruiting
2
4
Canada
JDQ443
Canadian Cancer Trials Group, Novartis
NSCLC
08/26
03/28
NCT02503722: Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer

Active, not recruiting
1
36
Canada, US
Laboratory Biomarker Analysis, Osimertinib, AZD 9291, AZD-9291, AZD9291, Mereletinib, Pharmacological Study, Sapanisertib, INK-128, INK128, MLN-0128, MLN0128, TAK-228
National Cancer Institute (NCI)
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
05/25
05/25
Hope, Andrew
NCT02381535: Onalespib in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin

Active, not recruiting
1
2
Canada, US
Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Intensity-Modulated Radiation Therapy, IMRT, Intensity modulated radiation therapy (procedure), Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy, Laboratory Biomarker Analysis, Onalespib, AT 13387, AT-13387, AT13387, Pharmacological Study
National Cancer Institute (NCI)
Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7
04/20
04/25
ASPIRE-ILD, NCT03485378: Assessment of Precision Irradiation in Early NSCLC and Interstitial Lung Disease

Active, not recruiting
N/A
39
Europe, Canada
Stereotactic Ablative Radiotherapy
Lawson Health Research Institute, London Health Sciences Centre, University of British Columbia, Western University, Canada
Non Small Cell Lung Cancer, Interstitial Lung Disease
01/22
09/26
MIRACLE, NCT05689437: MIRA Clinical Learning Environment (): Lung

Recruiting
N/A
1000
Canada
Application of ILD prediction machine learning model to planning imaging, Routine, automatic presentation of ILD risk level for evaluation by the clinician., Application of SGR machine learning model to diagnostic and planning imaging, Routine estimation of tumor specific growth rate (SGR) for lesions being considered for radiation therapy presented to clinician., Application of CBCT machine learning model to on-treatment imaging, Routine monitoring of lung density changes during the course of treatment presented to clinician.
University Health Network, Toronto, University of Toronto
Lung Cancer
12/23
12/23
Mattes, Malcolm
NCT05351294: Assessment of Early Radiation Oncology Involvement Alongside Standard Oncologic Care in the Managemet

Recruiting
3
156
US
Questionnaires, Early Radiation Oncology Involvement Alongside Standard Oncologic Care
Rutgers, The State University of New Jersey
Radiation Therapy, Metastatic Cancer
12/25
12/25
PREDICT-RT, NCT04513717: Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The Trial

Recruiting
3
2478
Canada, US
Apalutamide, ARN 509, ARN-509, ARN509, Erleada, JNJ 56021927, JNJ-56021927, Bicalutamide, Casodex, Cosudex, ICI 176,334, ICI 176334, Buserelin, 6-[O-(1,1-Dimethylethyl)-D-serine]-9-(N-ethyl-L-prolinamide)-10-deglycinamide-luteinizing Hormone-releasing Factor (Pig), BSRL, Busereline, Etilamide, HOE 766, ICI 123215, S74-6766, Degarelix, FE200486, Firmagon, Flutamide, 4'-Nitro-3'-trifluoromethylisobutyranilide, Apimid, Cebatrol, Chimax, Cytomid, Drogenil, Euflex, Eulexine, Flucinom, Flucinome, Flugerel, Fluken, Flulem, FLUT, Fluta-Gry, Flutabene, Flutacan, Flutamex, Flutamin, Flutan, Flutaplex, Fugerel, Grisetin, Niftolide, Oncosal, Profamid, Propanamide, 2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-, Prostacur, Prostadirex, Prostica, Prostogenat, Sch 13521, Tafenil, Tecnoflut, Testotard, Goserelin, ICI-118630, Histrelin, Leuprolide, Leuprorelin, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Radiation Therapy, Cancer Radiotherapy, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Triptorelin, 6-D-Tryptophan-LH-RH, 6-D-Tryptophanluteinizing Hormone-releasing Factor, AY-25650, CL-118,532, Detryptoreline
NRG Oncology, National Cancer Institute (NCI)
Metastatic Malignant Neoplasm in the Bone, Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
12/33
12/33
NADIR, NCT04037254: Niraparib With Standard Combination Radiation Therapy and Androgen Deprivation Therapy in Treating Patients With High Risk Prostate Cancer

Active, not recruiting
2
22
Canada, US
Gonadotrophin Releasing Hormone, AY-24031, D-His-6-Pro-8-NEt-LHRH, Follicle Stimulating Hormone-Releasing Factor, GN-RH, GnRH, Gonadoliberin, Gonadorelin, Gonadorelinum, gonadotropin-releasing hormone, Hoe- 471, LH-RF, LH-RH, LH/FSH-RF, LH/FSH-RH, LHRH, Luliberin, Luteinising Hormone-Releasing Factor, Luteinizing Hormone-Releasing Factor, luteinizing hormone-releasing hormone, Intensity-Modulated Radiation Therapy, IMRT, Intensity Modulated RT, Intensity-Modulated Radiotherapy, Niraparib, MK-4827, MK4827
NRG Oncology, National Cancer Institute (NCI)
Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
07/24
08/26
NCI-2021-13901, NCT05172245: Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer

Recruiting
1
46
Canada, US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Ipatasertib, GDC 0068, GDC-0068, GDC0068, RG 7440, RG-7440, RG7440, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation
National Cancer Institute (NCI)
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Carcinoma of Unknown Primary, Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced Hypopharyngeal Squamous Cell Carcinoma, Locally Advanced Laryngeal Squamous Cell Carcinoma, Locally Advanced Nasal Cavity Squamous Cell Carcinoma, Locally Advanced Oral Cavity Squamous Cell Carcinoma, Locally Advanced Oropharyngeal Squamous Cell Carcinoma, Locally Advanced Paranasal Sinus Squamous Cell Carcinoma, Locally Advanced Sinonasal Squamous Cell Carcinoma, Maxillary Sinus Squamous Cell Carcinoma, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage III Sinonasal Cancer AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Sinonasal Cancer AJCC v8, Stage IVB Hypopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Lip and Oral Cavity Cancer AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Sinonasal Cancer AJCC v8
06/26
06/26
NCT03716193: Measurement of the Partial Pressure of Oxygen in Cutaneous Tumors Using Electron Paramagnetic Resonance (EPR) Oximetry

Recruiting
N/A
40
US
Oxygen
West Virginia University, West Virginia Clinical and Translational Science Institute, Mary Babb Randolph Cancer Center at West Virginia University Hospitals
Skin Lesion, Skin Cancer, Skin Melanoma, Tumor Skin
07/24
07/24
Lheureux, Stephanie
innovaTV 301, NCT04697628 / 2019-001655-39: Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

Active, not recruiting
3
502
Europe, Canada, Japan, US, RoW
tisotumab vedotin, TIVDAK, topotecan, vinorelbine, gemcitabine, irinotecan, pemetrexed
Seagen Inc., Genmab
Cervical Cancer
07/23
08/25
ICON9, NCT03278717 / 2017-000161-75: Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients

Recruiting
3
330
Europe, Canada, RoW
Olaparib, Cediranib
University College, London, Cancer Research UK, AstraZeneca UK Limited
Ovarian Cancer
12/23
12/23
DOMENICA, NCT05201547 / 2021-002124-21: Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line

Recruiting
3
260
Europe, Canada, Japan, RoW
Carboplatin-Paclitaxel, Dostarlimab
ARCAGY/ GINECO GROUP, GlaxoSmithKline
Endometrial Cancer
04/26
10/29
NCT04510584: Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer

Withdrawn
2
20
Canada
Atezolizumab, TECENTRIQ, Bevacizumab, AVASTIN
University Health Network, Toronto
Ovarian Endometrioid Tumor, Fallopian Tube Cancer, Primary Peritoneal Cancer, TP53 Mutation
02/23
02/23
NCT03367741: Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer

Active, not recruiting
2
84
Canada, US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL 184, XL-184, XL184, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo
National Cancer Institute (NCI)
Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma, Recurrent Endometrial Carcinoma, Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
12/25
12/25
NCT03480776: ASA in Prevention of Ovarian Cancer (STICs and STONEs)

Active, not recruiting
2
117
Canada, RoW
Acetylsalicylic acid, ASA, Placebo
Canadian Cancer Trials Group, Apotex Inc.
Ovarian Cancer Prevention
06/25
12/25
CRI-CCTG-0003/IND.240, NCT04918186: Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer

Recruiting
2
60
Canada, US
Durvalumab, BA3011, BA3021, ENB003, Toripalimab
Canadian Cancer Trials Group, Cancer Research Institute, New York City, AstraZeneca, BioAtla, Inc.
Ovarian Cancer
06/25
12/25
NCI-2018-01503, NCT03587311: Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Active, not recruiting
2
96
Canada, US
Anetumab Ravtansine, BAY 94-9343, Bevacizumab, ABP 215, ABP-215, ABP215, Alymsys, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, Avzivi, Aybintio, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MB02, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-aybi, Bevacizumab-bvzr, Bevacizumab-equi, Bevacizumab-maly, Bevacizumab-onbe, Bevacizumab-tnjn, BP102, BP102 Biosimilar, CT P16, CT-P16, CTP16, Equidacent, FKB 238, FKB-238, FKB238, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, MB 02, MB-02, MB02, Mvasi, MYL-1402O, Onbevzi, Oyavas, PF 06439535, PF-06439535, PF06439535, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat
National Cancer Institute (NCI)
Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma
10/25
10/25
NCT05605509: RP-6306 in Patients With Advanced Cancer

Recruiting
2
78
Canada
RP-6306, Lunresertib, Gemcitabine, FOLFIRI Protocol, Trastuzumab, RP-3500, Camonsertib
Canadian Cancer Trials Group, Repare Therapeutics
Advanced Cancer
12/25
05/26
Re-VOLVE, NCT05065021: Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor

Recruiting
2
40
Canada
Niraparib, ZEJULA, Dostarlimab, Bevacizumab, Paclitaxel
University Health Network, Toronto, GlaxoSmithKline
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, High Grade Serous Cancer, High Grade Endometrioid Cancer
06/25
06/25
NCT03345784: Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers

Terminated
1
10
Canada, US
Adavosertib, AZD-1775, AZD1775, MK-1775, MK1775, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, External Beam Radiation Therapy, Definitive Radiation Therapy, EBRT, External Beam Radiation, External Beam Radiotherapy, External Beam Radiotherapy (conventional), External Beam RT, external radiation, External Radiation Therapy, external-beam radiation, Radiation, External Beam, Teleradiotherapy, Teletherapy, Teletherapy Radiation
National Cancer Institute (NCI)
Cervical Carcinoma, Endometrioid Adenocarcinoma, Malignant Female Reproductive System Neoplasm, Recurrent Cervical Carcinoma, Stage I Uterine Corpus Cancer AJCC v7, Stage I Vaginal Cancer AJCC v6 and v7, Stage IA Uterine Corpus Cancer AJCC v7, Stage IB Cervical Cancer AJCC v6 and v7, Stage IB Uterine Corpus Cancer AJCC v7, Stage IB2 Cervical Cancer AJCC v6 and v7, Stage II Cervical Cancer AJCC v7, Stage II Uterine Corpus Cancer AJCC v7, Stage II Vaginal Cancer AJCC v6 and v7, Stage IIA Cervical Cancer AJCC v7, Stage IIB Cervical Cancer AJCC v6 and v7, Stage III Cervical Cancer AJCC v6 and v7, Stage III Uterine Corpus Cancer AJCC v7, Stage III Vaginal Cancer AJCC v6 and v7, Stage IIIA Cervical Cancer AJCC v6 and v7, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Cervical Cancer AJCC v6 and v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Vaginal Carcinoma
05/22
05/22
Exactis-03, NCT05358639: Combination of Olaparib and Navitoclax in Women with HGSC and TNBC

Active, not recruiting
1
36
Canada
Olaparib tablet, Lynparza, Navitoclax, ABT-263
Sunnybrook Health Sciences Centre, Exactis Innovation, Centre hospitalier de l'Université de Montréal (CHUM), Princess Margaret Hospital, Canada
High Grade Serous Carcinoma, Triple Negative Breast Cancer, Ovarian Cancer
03/25
04/25
SGR-3515-101, NCT06463340: Study of SGR-3515 In Participants With Advanced Solid Tumors.

Recruiting
1
52
Canada, US
SGR-3515
Schrödinger, Inc.
Advanced Solid Tumor
10/26
12/26
GyneRep, NCT06107868: Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer

Active, not recruiting
1
24
Canada
RP-6306, Carboplatin, Paclitaxel
University Health Network, Toronto
Recurrent Ovarian Cancer, Recurrent Uterine Cancer, Metastatic Cancer, Advanced Cancer
12/26
12/26
NCT04373005: Screening of Cancer Patients to Assess Impact of COVID-19

Terminated
N/A
83
Canada
Nasopharyngeal (NP) swab
University Health Network, Toronto
Covid-19, Cancer
10/22
10/22
MAMBO, NCT03260647: Risk Stratified Multidisciplinary Ambulatory Management of Malignant Bowel Obstruction in Gynecological Cancers

Recruiting
N/A
150
Canada
Management algorithm for Malignant Bowel Obstruction
University Health Network, Toronto
Gynecologic Cancer
12/24
12/24
NeoCon-F, NCT04016389: FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery

Recruiting
N/A
90
Canada, US
Cisplatin, Carboplatin, Paclitaxel, Trachelectomy
University Health Network, Toronto, Hotel Dieu Hospital, The Netherlands Cancer Institute
Cervical Cancer
12/24
06/25
Butler, Marcus
NIMBLE, NCT04718389 / 2020-003612-28: A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

Hourglass Feb 2024 - Jun 2024 : Acceptance of regulatory submission in China for CRSwNP
Active, not recruiting
3
1667
Europe, Canada, Japan, US, RoW
GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS)
GlaxoSmithKline, Iqvia Pty Ltd
Asthma
10/25
10/25
STOP-GAP, NCT02821013: Duration of Anti-PD-1 Therapy in Metastatic Melanoma

Recruiting
3
614
Canada, RoW
Intermittent PD-1 inhibitor therapy, Continuous PD-1 inhibitor therapy
Canadian Cancer Trials Group, Melanoma and Skin Cancer Trials Limited
Unresectable/Metastatic Melanoma
12/27
12/29
DAR-UM-2, NCT05987332: IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Recruiting
2/3
420
Europe, Canada, US, RoW
IDE196, Darovasertib, Crizotinib, XALKORI, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Nivolumab, Opdivo, Dacarbazine, DTIC-Dome
IDEAYA Biosciences
Metastatic Uveal Melanoma
01/27
01/28
NCT05111574: Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery

Recruiting
2
99
Canada, US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL 184, XL-184, XL184, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Placebo Administration, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
National Cancer Institute (NCI)
Anal Melanoma, Bladder Melanoma, Cervical Melanoma, Esophageal Melanoma, Gallbladder Melanoma, Head and Neck Mucosal Melanoma, Mucosal Melanoma, Mucosal Melanoma of the Urinary System, Nasopharyngeal Mucosal Melanoma, Oral Cavity Mucosal Melanoma, Penile Mucosal Melanoma, Rectal Melanoma, Recurrent Mucosal Melanoma, Sinonasal Mucosal Melanoma, Stage II Vulvar Cancer AJCC v8, Stage III Vulvar Cancer AJCC v8, Stage IV Vulvar Cancer AJCC v8, Urethral Melanoma, Vaginal Melanoma, Vulvar Melanoma
12/25
12/25
IDE196-009, NCT05907954: (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

Recruiting
2
82
Europe, Canada, US, RoW
Darovasertib, IDE196, LXS196
IDEAYA Biosciences
Uveal Melanoma
01/26
01/29
NCT01883297: "Re-Stimulated" TILs and IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Active, not recruiting
1
3
NA
Re-stimulated tumor-infiltrating lymphocytes (TILs), Interleukin-2, Aldesleukin, Proleukin, Recombinant Human Interleukin 2, Cyclophosphamide, Procytox
University Health Network, Toronto
Recurrent, Platinum-resistant, High Grade Serous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
06/26
06/26
SURPASS, NCT04044859: ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors

Checkmark Results from SURPASS trial for MAGE-4 positive tumors
Sep 2022 - Sep 2022: Results from SURPASS trial for MAGE-4 positive tumors
Checkmark Clinical response data from SURPASS trial for solid tumors at CTOS 2019
Nov 2019 - Nov 2019: Clinical response data from SURPASS trial for solid tumors at CTOS 2019
Recruiting
1
120
Europe, Canada, US
Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks
Adaptimmune, ICON plc
Endometrial Cancer, Esophageal Cancer, Esophagogastric Junction (EGJ), Gastric (Stomach) Cancer, Head and Neck Cancer, Melanoma, Ovarian Cancer, Non-small Cell Lung (NSCLC), Urothelial Cancer
12/25
04/37
NCT02862275: Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer

Active, not recruiting
1
40
Canada, US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG 7446, RG-7446, RG7446, RO 5541267, RO-5541267, RO5541267, Tecentriq, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI
National Cancer Institute (NCI)
Hematopoietic and Lymphoid Cell Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
11/25
11/25
ANCHOR, NCT06171750: Phase I Study of ANK-101 in Advanced Solid Tumors

Recruiting
1
107
Canada, US
ANK-101, Cemiplimab, Libtayo
Ankyra Therapeutics, Inc
Advanced Solid Tumor, Cutaneous Tumor, Subcutaneous Tumor, Malignant Solid Tumor, Solid Tumor, Metastatic Solid Tumor, Metastasis to Soft Tissue, Non Small Cell Lung Cancer, Cutaneous Squamous Cell Carcinoma
07/25
01/26
NCT05963217: Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL

Recruiting
1
19
Canada
TBI-2001, Cyclophosphamide, Fludarabine
University Health Network, Toronto, Takara Bio Inc.
Relapsed or Refractory CD19+ B-cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma
03/25
05/26
STARLING, NCT05576077: A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors

Recruiting
1
60
Canada, US
TBio-4101, TIL, autologous, tumor-reactive, T-cell product, Pembrolizumab, Keytruda
Turnstone Biologics, Corp.
Breast Cancer, Colorectal Cancer, Uveal Melanoma, Cutaneous Melanoma, Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
12/24
06/25
NCT02636855: Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination

Recruiting
N/A
10000
Europe, Canada, US
Adaptimmune
Solid and Hematological Malignancies
11/25
11/25
Fuente, Macarena De La
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Calendar Jan 2030 - Dec 2030: Market entry for glioblastoma
Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28
NCT03224767: Vemurafenib and Cobimetinib in Treating Patients with BRAF V600E Mutation Positive Craniopharyngioma

Active, not recruiting
2
24
US
Vemurafenib, Cobimetinib, Laboratory Biomarker Analysis, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
BRAF V600E Mutation Present, Papillary Craniopharyngioma
10/26
08/28
NCT03212274: Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations

Active, not recruiting
2
145
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Olaparib, AZD 2281, AZD-2281, AZD2281, KU 0059436, KU-0059436, KU0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Glioblastoma, Recurrent Cholangiocarcinoma, Recurrent Glioma, Recurrent Malignant Solid Neoplasm, WHO Grade 2 Glioma, WHO Grade 3 Glioma
07/25
07/25
A071401, NCT02523014: Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients with Progressive Meningiomas

Recruiting
2
124
US
Vismodegib, GDC-0449, FAK Inhibitor GSK2256098, Capivasertib, AZD5363, Abemaciclib
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), GlaxoSmithKline, Genentech, Inc., Brain Science Foundation
Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
01/26
01/28
 

Download Options